Literature DB >> 1810599

Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.

E Winslow1, J K Campbell, E Barron, R J Marshall, A W Muir.   

Abstract

1. The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo. In addition the haemodynamic effects of Org 7797 were assessed in greyhounds. 2. Org 7797 (0.5 mg kg-1) significantly reduced the expected incidence of early ischaemia-induced ventricular fibrillation (VF) in rats and greyhound dogs and at doses of 0.5-1.0 mg kg-1 antagonized reperfusion-induced arrhythmias. Comparative studies in rats showed Org 7797 to be 2-4 times more potent than flecainide or propafenone. 3. Org 7797 (0.5 mg kg-1) slowed intracardiac conduction in anaesthetized beagles and again was at least 2-4 times more potent than flecainide or propafenone. 4. Org 7797 (0.5 and 2.0 mg kg-1), flecainide (1.0 and 2.0 mg kg-1) or propafenone (0.5 and 2.0 mg kg-1), did not significantly prevent induction of tachyarrhythmias (VT) in dogs with 5-6 day old myocardial infarcts although all 3 drugs appeared to prevent induced VF. All 3 drugs (notably flecainide) did however reduce the VT rate. 5. All 3 drugs (1-2 mg kg-1) suppressed spontaneous tachyarrhythmias in conscious beagle dogs with 1-2 day old infarcts. Propafenone was the least effective. 6. In an antifibrillatory dose (0.5 mg kg-1), the major haemodynamic effect of Org 7797 was a 10% increase in peripheral vascular resistance. Stroke volume, cardiac output and coronary blood flow were unchanged. In therapeutic doses, Org 7797 was also less negatively chronotropic than flecainide.7. It was concluded that Org 7797 is a potent antifibrillatory agent which is haemodynamically well tolerated. Higher doses are required to suppress late ischaemia-induced tachyarrhythmias which suggest that its antifibrillatory effects are the consequence of an action other than, or in addition to, sodium channel block.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810599      PMCID: PMC1908862          DOI: 10.1111/j.1476-5381.1991.tb12517.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Antiarrhythmic drug classification: new science and practical applications.

Authors:  D C Harrison
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

2.  Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs.

Authors:  E Winslow; M Martorana; P Bell
Journal:  J Cardiovasc Pharmacol       Date:  1989-08       Impact factor: 3.105

Review 3.  Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction.

Authors:  M J Janse; A L Wit
Journal:  Physiol Rev       Date:  1989-10       Impact factor: 37.312

4.  Propafenone interacts stereoselectively with beta 1- and beta 2-adrenergic receptors.

Authors:  D M Burnett; J Gal; N R Zahniser; A S Nies
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

5.  Electrophysiology underlying ventricular arrhythmias due to coronary ligation.

Authors:  B J Scherlag; R H Helfant; J I Haft; A N Damato
Journal:  Am J Physiol       Date:  1970-12

6.  Effects of flecainide on occlusion and reperfusion arrhythmias in dogs.

Authors:  S N Lederman; T L Wenger; D E Bolster; H C Strauss
Journal:  J Cardiovasc Pharmacol       Date:  1989-04       Impact factor: 3.105

7.  Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.

Authors:  J K Campbell; R T Logan; R J Marshall; G McGarry; T Sleigh; E Winslow
Journal:  J Med Chem       Date:  1986-02       Impact factor: 7.446

8.  Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs.

Authors:  C Kirchhof; M Wijffels; J Brugada; J Planellas; M Allessie
Journal:  J Cardiovasc Pharmacol       Date:  1991-01       Impact factor: 3.105

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion.

Authors:  M J Walker; M J Curtis; D J Hearse; R W Campbell; M J Janse; D M Yellon; S M Cobbe; S J Coker; J B Harness; D W Harron
Journal:  Cardiovasc Res       Date:  1988-07       Impact factor: 10.787

View more
  2 in total

Review 1.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

2.  Electrophysiological effects of Org 7797 in the closed-chest anaesthetized dog.

Authors:  J Leboeuf; M Basiez; R Massingham
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.